ACh release was not blocked by pertussis toxin, supporting the conclusion that the hypocretin receptors modulating ACh release in rat PnO activate stimulatory G proteins. Hypocretin-1 and hypocretin-2 each caused a concentration dependent increase in ACh release with similar potencies, indicating that hcrt-r2 modulates ACh release in PnO. Hypocretin-1 caused a significantly greater increase in ACh release than hypocretin-2, suggesting a role for hcrt-r1 in the modulation of PnO ACh release. Taken together, these data provide the first evidence that hypocretin receptors in rat PnO signal via inhibitory and stimulatory G proteins, and that ACh release in rat PnO is modulated by hcrt-r2 and hcrt-r1. One mechanism by which hypocretin promotes arousal may be to increase ACh release in the pontine reticular formation.
JPET #97071

Introduction
Hypocretin-1 and hypocretin-2 (orexin A and orexin B) are neuropeptides synthesized by a small group of lateral hypothalamic neurons that project extensively throughout the brain Peyron et al., 1998; Sakurai et al., 1998) . Physiological roles of the hypocretin peptides include promoting behavioral arousal and locomotor activity, as well as modulating food intake and energy homeostasis (Kukkonen et al., 2002; Smart and Jerman, 2002) . Impaired hypocretinergic signaling underlies the human sleep disorder narcolepsy (Nishino et al., 2000; Thannickal et al., 2000) , and defects in hypocretin peptides or receptors produce animal models of narcolepsy (Chemelli et al., 1999; Lin et al., 1999) . The mechanisms by which hypocretins modulate arousal are not well understood, and may include excitation of brainstem neurons that promote behavioral arousal and cortical activation (Kilduff and Peyron, 2000) . Hypocretinergic neurons discharge at their fastest rates during active wakefulness (Lee et al., 2005; Mileykovskiy et al., 2005) , and hypocretins have excitatory effects on noradrenergic neurons of the locus coeruleus, serotonergic neurons of the dorsal raphe, and cholinergic neurons of the laterodorsal and pedunculopontine tegmental nuclei (reviewed in Kukkonen et al., 2002) .
Hypocretin-1 and hypocretin-2 alter cell excitability via two receptor subtypes (hcrt-r1 and hcrt-r2) (Sakurai et al., 1998) . Hypocretin-1 has relatively high affinity for both receptor subtypes, whereas hypocretin-2 has higher affinity for hcrt-r2 than for hcrt-r1 (Sakurai et al., 1998; Smart et al., 2001) . Both hypocretin receptor subtypes couple to guanine nucleotide binding (G) proteins (Sakurai et al., 1998) . Pertussis toxin is a standard pharmacological tool for blocking signal transduction mediated by inhibitory G proteins (Carty, 1994) , and work with in vitro expression systems has shown that hcrt-r2 couples to both pertussis toxin-insensitive and This article has not been copyedited and formatted. The final version may differ from this version. 5 pertussis toxin-sensitive G proteins (Zhu et al., 2003) . The G protein subtypes coupled to each hypocretin receptor subtype in vivo remain to be determined, and may vary across brain regions.
The present study focused on functional effects of hypocretin in one arousal promoting brainstem region, the oral part of the pontine reticular nucleus (PnO). The PnO is the rostral portion of rat pontine reticular formation (Paxinos and Watson, 1998) . In vivo and in vitro approaches were combined with the goal of identifying mechanisms by which the arousal promoting peptide hypocretin acts within the PnO, which comprises an important part of the ascending reticular activating system. In vitro autoradiography was used to test the hypothesis that treatment of the PnO with pertussis toxin inhibits hypocretin-1-stimulated [ 35 This article has not been copyedited and formatted. The final version may differ from this version. Washington, DC, 1996) and with approval by the University of Michigan Committee on Use and
Care of Animals. All in vivo experiments were performed under general anesthesia using the following procedure. A rat was placed in a Plexiglas chamber and anesthesia was induced with isoflurane (2-3 % in 100% O 2 ). The anesthetized rat then was placed in a stereotaxic frame (David Kopf, Tujunga, CA) and isoflurane was delivered through a rat anesthesia mask (David Kopf) using a flow rate of 0.6 L O 2 /min. Delivered isoflurane levels were measured continuously with an infrared gas analyzer (Cardiocap ™ /5, Datex-Ohmeda, Louisville, CO) and held at 1.5% throughout the experiment. A re-circulating heat pump (Gaymar Industries, Orchard Park, NY) was used to maintain core body temperature at 37ºC. Using a Dremel (Racine, WI), a small hole was made in the skull to permit unilateral access to the PnO according to a rat brain atlas (Paxinos and Watson, 1998) . Stereotaxic coordinates for the PnO were 8.6 mm posterior to bregma, 1.2 mm from the midline, and 9.2 mm ventral to the skull surface.
Animals were kept warm and observed continuously during recovery from anesthesia. Histological localization of dialysis sites. Two to three days following each dialysis experiment, animals were deeply anesthetized and decapitated. The brainstem was cut serially to obtain 40 µm thick coronal sections through the pontine reticular formation. Tissue sections were mounted on chrome alum coated slides, fixed in paraformaldehyde vapor (80°C), and stained with cresyl violet. Stained sections were digitized using a Cohu CCD camera with a Micro Nikon 60 mm objective, the Scion Image 1.62c version of NIH Image, and a G3 Apple Macintosh computer. Stereotaxic coordinates were assigned to each dialysis probe site by comparing the digitized images and actual tissue sections to the plates in a rat brain atlas (Paxinos and Watson, 1998) .
Chemicals
This article has not been copyedited and formatted. The final version may differ from this version. The alpha level was set at p<0.05, and power calculations were performed to ensure using the smallest number of animals required to achieve a beta level of 80%.
This article has not been copyedited and formatted. The final version may differ from this version. Methods for testing the hypothesis that pretreatment of the PnO with pertussis toxin inhibits hypocretin-1-stimulated ACh release in the PnO: in vivo microinjection followed by in vivo microdialysis. Animals were surgically prepared with guide tubes aimed for the PnO and microinjected with pertussis toxin or pertussis toxin vehicle as described above. Forty-eight h after pertussis toxin administration, rats were anesthetized with isoflurane and a dialysis probe was placed through the guide tube into the PnO. Dialysis samples (30 µl) were collected every 15 min. Five samples were collected during dialysis with Ringer's to establish baseline levels of ACh release. A CMA/110 liquid switch then was turned to deliver Ringer's containing hypocretin-1 (100 µM) to the probe. Five sequential dialysis samples were collected during continuous PnO administration of hypocretin-1. The probe then was removed from the brain.
Brainstems were processed for cresyl violet histology, as described above.
Positive control experiments were performed using dialysis administration of the adenosine A 1 receptor agonist SPA (300 µM). Adenosine A 1 receptors couple to pertussis toxinsensitive G proteins (Ribeiro et al., 2003) and SPA decreases ACh release in cat pontine reticular formation (Tanase et al., 2003) . Thus, pretreatment with pertussis toxin was predicted to inhibit the SPA-induced decrease in ACh release, and pretreatment with pertussis toxin vehicle was predicted to have no effect on the SPA-induced decrease in ACh release.
ACh release during dialysis administration of hypocretin-1 or SPA was expressed as a percent of baseline ACh measured during dialysis with Ringer's for each experiment. Data were analyzed by descriptive statistics and two-way ANOVA (Statistical Analysis System (SAS) software, release 9.1.2, SAS Institute, Inc., Cary, NC). A significant ANOVA was followed by a were collected during continuous hypocretin delivery. When the last dialysis sample was collected, the probe was removed from the brain, the scalp was closed, and the animal recovered from anesthesia. Brains were processed for cresyl violet histology two to three days later, as described above.
Data were analyzed using descriptive and inferential statistics. The alpha level for statistical significance was set at p<0.05. The smallest number of animals required to achieve a beta level of 80% was established using power calculations. Additional control experiments involved unilateral microinjection of the pertussis toxin vehicle into the PnO 48 h before brain removal for autoradiography (Fig. 1D) . Figure 1E summarizes the effects of vehicle microinjection on basal and hypocretin-1-stimulated Figure 2 localizes the microdialysis sites used to test the hypothesis that pretreatment with pertussis toxin blocks hypocretin-1-stimulated ACh release. All probe sites were located in the PnO.
Pertussis toxin did not inhibit hypocretin-1-stimulated ACh release.
Bonferroni t-test revealed that the average ± s.e.m. stereotaxic coordinates for pertussis toxin injection sites (8.04 ± 0.11 mm posterior to bregma; 1.38 ± 0.07 mm lateral to bregma; 9.18 ± 0.12 mm ventral to bregma) were not significantly different from the stereotaxic coordinates for vehicle injection sites (8.13 ± 0.06 mm posterior to bregma; 1.18±0.04 mm lateral to bregma; 9.13 ± 0.10 mm ventral to bregma). (Fig. 3A) .
The adenosine A 1 receptor agonist SPA served as a positive control for the effects of pertussis toxin. Figure 3B illustrates results from six rats (n=60 dialysis samples) that underwent dialysis administration of SPA following pretreatment with pertussis toxin or vehicle. Two-way ANOVA showed a significant effect of dialysis condition (Ringer's vs. SPA) on ACh release (F=17.5; df=1,52; p<0.0001), a significant effect of pretreatment (vehicle vs. pertussis toxin) on ACh release (F=10.6; df=1,4; p=0.03), and a significant interaction (F=10.6; df=1,52; p=0.002).
SPA significantly (p<0.0001) decreased (-30.7%) ACh release in the PnO after vehicle microinjection. The SPA-induced decrease in ACh release was blocked by pretreatment with pertussis toxin. SPA-stimulated ACh release after vehicle microinjection was significantly (p=0.0002) lower (-28.0%) than SPA-stimulated ACh release following pertussis toxin microinjection. Mean ± s.e.m. basal (Ringer's) ACh levels (pmol/15 min) were 0.081 ± 0.005 for vehicle injection experiments and 0.123 ± 0.006 for pertussis toxin injection experiments (Fig. 3B ).
Hypocretin-1 and hypocretin-2 each caused a concentration dependent increase in
ACh release. Figure 4 summarizes the location of all dialysis sites used for the concentration response studies. Figure 4A shows representative histological sections from a rat that received This article has not been copyedited and formatted. The final version may differ from this version. hypocretin-1 (6.0 ± 0.2%) and hypocretin-2 (6.4 ± 0.3%) also was not significantly different.
These measures provided important controls indicating that differences reported below (Figs. 5 and 6) in the magnitude of the ACh response to equimolar concentrations of hypocretin-1 and hypocretin-2 were not artifacts due to differences in intrapontine site of hypocretin delivery or differences in amounts of ACh recovered by the dialysis probes. (Fig. 5A ) or 0.1 µM hypocretin-2 (Fig. 5E ) did not alter ACh release. Figure 5B shows that 1 µM hypocretin-1 significantly increased ACh release during the second 15 min sampling period. In contrast, 1 µM hypocretin-2 did not increase ACh release (Fig. 5F ).
Dialysis with 10 and 100 µM hypocretin-1 (Fig. 5C and 5D ) caused significant increases in ACh release. In contrast to Fig. 5E , 5F, and 5G, only the 100 µM concentration of hypocretin-2 significantly increased ACh release (Fig. 5H ). There was no significant difference between This article has not been copyedited and formatted. The final version may differ from this version. Fig. 5E-H) . This finding supports the interpretation that differences in the magnitude of the ACh response to equimolar concentrations of hypocretin-1 and hypocretin-2 were not artifacts resulting from differences in basal levels of ACh release. Hypocretin receptors activate pertussis toxin-sensitive G proteins in rat PnO. In vitro [ 35 S]GTPγS autoradiography has been used successfully to quantify the functional activity of many different G protein coupled receptors (Sóvágó et al., 2001 ). Agonist activated
GTPγS binding in brain is thought to preferentially label inhibitory (Gi/o, Gz), rather than stimulatory (Gs, Gq) G proteins (Sóvágó et al., 2001; Harrison and Traynor, 2003; Laitinen, 2004) . Pertussis toxin selectively inactivates Gi/o proteins and pertussis toxin has been shown to be effective following microinjection into rat striatum (van der Ploeg et al., 1991) , ventral tegmental area (Gronier and Rasmussen, 1999) , substantia nigra compacta (Gronier and This article has not been copyedited and formatted. The final version may differ from this version. Rasmussen, 1999), and hippocampus (Tzavara et al., 2003) . The present finding that PnO microinjection of pertussis toxin decreased hypocretin-1-stimulated [ 35 S]GTPγS binding in the PnO (Fig.1B) is the first direct evidence that hypocretin activates inhibitory G proteins in rat pontine reticular formation. This result is consistent with the interpretation that some hypocretin receptors in rat PnO couple to Gi/o proteins. An alternative explanation is that PnO hypocretin receptors indirectly activate Gi/o proteins via G protein cross talk (Vazquez-Prado et al., 2003) or heterodimerization of hypocretin receptors (Karteris and Randeva, 2003) with other Gi/o protein coupled receptors (Devi, 2001 ).
To further test the interpretation that hypocretin-1 activates Gi/o proteins in rat PnO, the effects of pertussis toxin on DAMGO-stimulated [ 35 S]GTPγS binding also were quantified. The mu opioid agonist DAMGO was used as a positive control because mu opioid receptors couple exclusively to Gi/o proteins (Birnbaumer et al., 1990) . DAMGO-stimulated [ 35 S]GTPγS binding was significantly reduced by pretreatment with pertussis toxin (Fig. 1C , compare filled bars), confirming that microinjection of pertussis toxin effectively inactivated Gi/o proteins in the PnO.
DAMGO-stimulated [ 35 S]GTPγS binding was not completely eliminated by pretreatment with
pertussis toxin (Fig. 1C: PTX injection, hatched versus filled bar, ). A higher concentration of pertussis toxin than was used in the present study may be required to eliminate the remaining DAMGO-stimulated G protein activation. Alternatively, the remaining DAMGO-stimulated G protein activation may have resulted from activating mu opioid receptors that couple to pertussis toxin-insensitive inhibitory G proteins (Gz) (Ho and Wong, 2001 it is concentration dependent and blocked by specific hypocretin receptor antagonists (Shiba et al., 2002; Bernard et al., 2003; Bernard et al., 2005) . Therefore, the Fig. 1 results support the conclusion that some hypocretin receptors in rat PnO couple to pertussis toxin-sensitive inhibitory G proteins. This conclusion is consistent with in vitro electrophysiological data
showing that hypocretin-induced alterations in cell excitability are inhibited by pertussis toxin (Hoang et al., 2003; van den Top et al., 2003; Zhu et al., 2003; Holmqvist et al., 2005) .
Hypocretin-1-stimulated ACh release in the PnO is mediated by pertussis toxininsensitive G proteins. The present study aimed to determine if one mechanism by which hypocretin modulates ACh release includes activation of pertussis toxin-sensitive G proteins in rat PnO. Using the same protocol shown to be effective for blocking hypocretin-1-stimulated G protein activation (Fig. 1) , pertussis toxin was microinjected into the PnO 48 h before dialysis administration of hypocretin-1 or SPA (Fig. 2) . Positive control experiments utilized the adenosine A 1 receptor agonist SPA, which is known to activate pertussis toxin-sensitive G proteins (Ribeiro et al., 2003) and inhibit ACh release (Tanase et al., 2003) . Pertussis toxin blocked the SPA-induced decrease in ACh release (Fig. 3B) , confirming that Gi/o proteins were inactivated. In contrast, the hypocretin-1-induced increase in ACh release was not blocked by pertussis toxin (Fig. 3A) , suggesting that hypocretin-1-stimulated ACh release is mediated by This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3 ).
The conclusion that hypocretin receptors modulating ACh release in PnO couple to stimulatory G proteins is consistent with the neuroexcitatory activity of hypocretin . Hypocretin receptors also have been suggested to signal through Gq proteins Zhu et al., 2003) , which are known to stimulate phosphoinositol turnover and increase intracellular Ca 2+ . Hypocretin-1-stimulated calcium release in Chinese hamster ovary cell lines (Smart et al., 1999) and in hypothalamic neurons involves phospholipase C and/or protein kinase C. Alternatively, hypocretin-1 could stimulate ACh release via pertussis toxin-insensitive inhibitory G proteins (Knott et al., 1993) . However, the present observation that pertussis toxin inhibits hypocretin-1-stimulated G protein activation (Fig. 1) suggests that in rat PnO, some hypocretin receptors couple to inhibitory G proteins that are indeed pertussis toxin-sensitive. In addition, the values (Fig. 6) , consistent with the interpretation that hcrt-r2 modulates ACh release in the PnO (Sakurai et al., 1998; Smart et al., 1999; Smart et al., 2001) . At concentrations of 10 µM and 100
This article has not been copyedited and formatted. The final version may differ from this version. 6 ), suggesting that hcrt-r1 also may be involved in modulating PnO ACh release. Both hypocretin receptor subtypes are expressed in rat PnO (Greco and Shiromani, 2001 ). Thus, these data provide novel evidence that ACh release in rat PnO is modulated by hcrt-r2 and hcrt-r1.
Functional Implications. One new finding presented here is that rat PnO contains a population of hypocretin receptors that activate pertussis toxin sensitive G proteins (Fig. 1) . The function served by hypocretinergic activation of putatively inhibitory G proteins is unknown.
The present study also showed, for the first time, that hypocretin-1 causes a pertussis toxin insensitive increase in ACh release within the PnO (Fig. 3) , and that both peptides evoke a concentration dependent increase in PnO ACh release (Fig. 6 ). These data provide the first functional evidence that hypocretin receptors in rat PnO activate stimulatory G proteins.
Increasing ACh release in PnO may be one mechanism by which hypocretin promotes brain activation. Cholinergic transmission in the pontine reticular formation participates in generating the cortical activation characteristic of wakefulness and rapid eye movement sleep , and microinjection of hypocretin-1 into cat pontine reticular formation can trigger REM sleep (Xi et al., 2002) . Interactions between cholinergic and GABAergic transmission in the pontine reticular formation promote wakefulness, particularly when GABAergic transmission is enhanced (Xi et al., 2004) . Most recently, hypocretin-1 has been shown to cause a concentration dependent increase in PnO GABA levels (Soto-Calderon et al., 2005) . Taken together, these findings are consistent with the interpretation that hypocretin promotes arousal, in part, by increasing ACh release in PnO.
This article has not been copyedited and formatted. The final version may differ from this version. Pretreatment with pertussis toxin inhibited hypocretin-1-stimulated G protein activation.
Coronal brainstem plates were modified from a rat brain atlas (Paxinos and Watson, 1998 
Figure 4
Sites for dialysis administration of hypocretin-1 and hypocretin-2 were localized to the pontine reticular nucleus, oral part (PnO). Coronal plates spanning from bregma -7.80 mm to -8.72 mm were modified from a rat brain atlas (Paxinos and Watson, 1998) . Cylinders indicating dialysis membranes are drawn to scale. A, digitized images of cresyl violet stained coronal brainstem sections show representative dialysis sites from two rats. Arrows indicate the deepest portion of the dialysis membranes. B, dialysis sites from experiments that examined the effect of hypocretin-1 on ACh release were all within the PnO. Twelve rats (3 per concentration) were used for these studies. Each rat was used only once. C, dialysis sites for determining the effects of hypocretin-2 on ACh release were confirmed to be in the PnO. Twelve rats (3 per concentration) were used for these studies. Each rat was used only once.
This article has not been copyedited and formatted. The final version may differ from this version. Concentration response curves for ACh release stimulated by hypocretin-1 and hypocretin-2.
Data were obtained from three experiments per concentration for each peptide. The coefficients of determination (r 2 ) indicated that 99.9 and 100% of the variability in ACh was accounted for
